Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Exact Sciences Corporation reported a robust third-quarter performance in 2025, demonstrating substantial growth and strategic advancements across its portfolio.</li><li>The company's total revenue increased by 20% year-over-year, reaching $851 million.</li><li>This growth was predominantly driven by the expansion of their screening division, particularly the Cologuard brand, which saw revenues surge by 22% to $666 million.</li></ul>

Exact Sciences Corporation reported a robust third-quarter performance in 2025, demonstrating substantial growth and strategic advancements across its portfolio.The company's total revenue increased by 20% year-over-year, reaching $851 million.This growth was predominantly driven by the expansion of their screening division, particularly the Cologuard brand, which saw revenues surge by 22% to $666 million.

Exact Sciences: How Cologuard Plus Could Unlock a New Wave of Market Expansion?

<ul><li>Exact Sciences Corporation reported its financial results for the second quarter of 2025.</li><li>The company delivered strong performance metrics and revised its financial guidance upward, reflecting solid growth across its operations.</li><li>Exact Sciences processed a record 1.3 million test results during the quarter, which contributed to a 16% yearover-year increase in core revenue.</li></ul>

Exact Sciences Corporation reported its financial results for the second quarter of 2025.The company delivered strong performance metrics and revised its financial guidance upward, reflecting solid growth across its operations.Exact Sciences processed a record 1.3 million test results during the quarter, which contributed to a 16% yearover-year increase in core revenue.

Exact Sciences Reinforces Its Market Edge With Strategic Alliances & Profit Growth!

<ul><li>Exact Sciences' first quarter 2025 financial results reflect a blend of robust revenue growth, strategic commercial execution, and significant advancements in their product pipeline.</li><li>The company's financial performance this quarter includes an 11% increase in total revenue, reaching $707 million, outpacing the midpoint of their guidance.</li><li>This growth is largely driven by their Screening segment, which saw revenue rise by 14% to $540 million, fueled by successful rescreen initiatives, improved commercial strategies, and the rollout of Cologuard Plus.</li></ul>

Exact Sciences' first quarter 2025 financial results reflect a blend of robust revenue growth, strategic commercial execution, and significant advancements in their product pipeline.The company's financial performance this quarter includes an 11% increase in total revenue, reaching $707 million, outpacing the midpoint of their guidance.This growth is largely driven by their Screening segment, which saw revenue rise by 14% to $540 million, fueled by successful rescreen initiatives, improved commercial strategies, and the rollout of Cologuard Plus.

Exact Sciences: Launch of Cologuard Plus to Redefine Colorectal Cancer Screening Paradigm!

<ul><li>Exact Sciences recently reported its fourth-quarter 2024 financial results, showcasing a mix of both positive momentum and certain challenges.</li><li>For the full year, Exact Sciences achieved a core revenue growth of 11%, reaching $2.75 billion, and notably expanded its adjusted EBITDA by nearly 48%.</li><li>The company also doubled its free cash flow and ended the year with a robust $1.04 billion in cash and securities.</li></ul>

Exact Sciences recently reported its fourth-quarter 2024 financial results, showcasing a mix of both positive momentum and certain challenges.For the full year, Exact Sciences achieved a core revenue growth of 11%, reaching $2.75 billion, and notably expanded its adjusted EBITDA by nearly 48%.The company also doubled its free cash flow and ended the year with a robust $1.04 billion in cash and securities.

Exact Sciences Corporation: Is The Oncology Product Pipeline Development to Capture A Lion’s Share of the Market?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We had been near-term bullish on the S&amp;P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral</li>
<li>The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here</li>
<li>Still, our intermediate-term outlook remains bullish (as of 5/14/25 report), and we'll maintain our bullish intermediate-term view as long as market dynamics remain constructive and the SPX is above 6200</li>
</ul>


We had been near-term bullish on the S&amp;P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral
The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here
Still, our intermediate-term outlook remains bullish (as of 5/14/25 report), and we'll maintain our bullish intermediate-term view as long as market dynamics remain constructive and the SPX is above 6200


Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight

United States

Exact Sciences Corp., is focused on developing and commercializing a non-invasive molecular screening test for the early detection and prevention of colorectal cancer. The Company's test is a stool-based DNA test that identifies both pre-cancer and cancer by detecting genetic mutations in colorectal cancer cells.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Exact Sciences (EXAS US)

Exact Sciences: How Cologuard Plus Could Unlock a New Wave of Market Expansion?

Exact Sciences Corporation reported a robust third-quarter performance in 2025, demonstrating substantial growth and strategic advancements across...

Baptista Research

Exact Sciences Reinforces Its Market Edge With Strategic Alliances & Profit Growth!

Exact Sciences Corporation reported its financial results for the second quarter of 2025. The company delivered strong performance metrics and...

Baptista Research

Exact Sciences: Launch of Cologuard Plus to Redefine Colorectal Cancer Screening Paradigm!

Exact Sciences' first quarter 2025 financial results reflect a blend of robust revenue growth, strategic commercial execution, and significant...

Baptista Research

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight

Coasting as We Stalk for Buying Opportunity; Downgrading Near-Term Outlook to Neutral, But Still Bullish Intermediate-Term $SPX $QQQ; Downgrading...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Exact Sciences: How Cologuard Plus Could Unlock a New Wave of Market Expansion?

Exact Sciences Corporation reported a robust third-quarter performance in 2025, demonstrating substantial growth and strategic advancements across...

Baptista Research

Exact Sciences Reinforces Its Market Edge With Strategic Alliances & Profit Growth!

Exact Sciences Corporation reported its financial results for the second quarter of 2025. The company delivered strong performance metrics and...

Baptista Research

Exact Sciences: Launch of Cologuard Plus to Redefine Colorectal Cancer Screening Paradigm!

Exact Sciences' first quarter 2025 financial results reflect a blend of robust revenue growth, strategic commercial execution, and significant...

Baptista Research

Exact Sciences Corporation: Is The Oncology Product Pipeline Development to Capture A Lion’s Share of the Market?

Exact Sciences recently reported its fourth-quarter 2024 financial results, showcasing a mix of both positive momentum and certain challenges. For...

Baptista Research

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight

Coasting as We Stalk for Buying Opportunity; Downgrading Near-Term Outlook to Neutral, But Still Bullish Intermediate-Term $SPX $QQQ; Downgrading...

Vermilion Research